• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

淋巴结比率可预测阳性淋巴结非小细胞肺癌患者的癌症特异性生存:基于人群的 SEER 分析。

The lymph node ratio predicts cancer-specific survival of node-positive non-small cell lung cancer patients: a population-based SEER analysis.

机构信息

Department of Thoracic Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, Zhejiang Province, China.

Department of surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 east qing chun road, Hangzhou, 310016, Zhejiang Province, China.

出版信息

J Cardiothorac Surg. 2021 Jan 19;16(1):13. doi: 10.1186/s13019-020-01390-x.

DOI:10.1186/s13019-020-01390-x
PMID:33468199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7814600/
Abstract

BACKGROUND

Lymph node ratio (LNR) has been suggested to be an effective prognostic tool for stratifying non-small cell lung cancer (NSCLC) cases. In this study, we sought to determine cancer-specific survival (CCS) of NSCLC cases from the SEER registry and used the X-tile method to optimize CCS-based LNR cut-off points for prognostic stratification of node-positive NSCLC.

METHODS

CSS and other clinicopathologic variables were retrieved from the SEER registry. Kaplan-Meier methods were used to calculate CSS. The optimal cut-off points for LNR classification were determined by the X-tile approach. Multivariate Cox regression analysis was performed to identify independent risks of CSS.

RESULTS

Totally 11,341 lung cancer patients were included. Their median CSS was 22 months (range 0,143). The median LNR was 0.22 (Q1,Q3: 0.11, 0.50). X-tile analysis showed that the optimal LNR cut-off points were 0.28 and 0.81, dividing the cohort into low (LNR1 ≤ 0.28; n = 6580, 58%), middle (0.28 < LNR2 < 0.81; n = 3025, 26.7%), and high (LNR3 > 0.81; n = 1736, 15.3%) subsets. Kaplan-Meier analysis showed that patients with a low LNR had a significantly higher CCS versus patients with middle or high LNR (P < 0.001). Multivariate competing risks regression analysis revealed that LNR was an independent and significant adverse predictor of CSS (LNR2 vs. LNR1: SHR: 1.56, 95%CI: 1.47,1.67, P < 0.001; LNR3 vs. LNR1: SHR: 2.54, 95%CI: 2.30,2.80, P < 0.001).

CONCLUSIONS

LNR is an independent prognostic factor of node-positive NSCLC and its optimal cut-off values established using the robust x-tile method effectively define subpopulations of node-positive NSCLC cases, which is important in guiding selection of treatment strategies clinically.

摘要

背景

淋巴结比率(LNR)已被证明是一种有效的非小细胞肺癌(NSCLC)分层预后工具。本研究旨在通过 SEER 数据库确定 NSCLC 患者的癌症特异性生存率(CSS),并使用 X-tile 方法确定基于 CSS 的 LNR 截断点,以对淋巴结阳性 NSCLC 进行预后分层。

方法

从 SEER 数据库中检索 CSS 和其他临床病理变量。Kaplan-Meier 方法用于计算 CSS。通过 X-tile 方法确定 LNR 分类的最佳截断点。多因素 Cox 回归分析用于确定 CSS 的独立风险因素。

结果

共纳入 11341 例肺癌患者。中位 CSS 为 22 个月(范围 0,143)。中位 LNR 为 0.22(Q1,Q3:0.11,0.50)。X-tile 分析显示,最佳 LNR 截断点为 0.28 和 0.81,将队列分为低(LNR1≤0.28;n=6580,58%)、中(0.28<LNR2<0.81;n=3025,26.7%)和高(LNR3>0.81;n=1736,15.3%)亚组。Kaplan-Meier 分析显示,低 LNR 患者的 CSS 明显高于中或高 LNR 患者(P<0.001)。多因素竞争风险回归分析显示,LNR 是 CSS 的独立且显著的不良预测因子(LNR2 与 LNR1:SHR:1.56,95%CI:1.47,1.67,P<0.001;LNR3 与 LNR1:SHR:2.54,95%CI:2.30,2.80,P<0.001)。

结论

LNR 是淋巴结阳性 NSCLC 的独立预后因素,使用稳健的 X-tile 方法确定的最佳截断值可有效定义淋巴结阳性 NSCLC 病例的亚群,这对指导临床治疗策略的选择具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42fc/7814600/3472765d7445/13019_2020_1390_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42fc/7814600/fb4c971d6984/13019_2020_1390_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42fc/7814600/f334ac960aa1/13019_2020_1390_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42fc/7814600/0c57ae73a8ff/13019_2020_1390_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42fc/7814600/3472765d7445/13019_2020_1390_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42fc/7814600/fb4c971d6984/13019_2020_1390_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42fc/7814600/f334ac960aa1/13019_2020_1390_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42fc/7814600/0c57ae73a8ff/13019_2020_1390_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42fc/7814600/3472765d7445/13019_2020_1390_Fig4_HTML.jpg

相似文献

1
The lymph node ratio predicts cancer-specific survival of node-positive non-small cell lung cancer patients: a population-based SEER analysis.淋巴结比率可预测阳性淋巴结非小细胞肺癌患者的癌症特异性生存:基于人群的 SEER 分析。
J Cardiothorac Surg. 2021 Jan 19;16(1):13. doi: 10.1186/s13019-020-01390-x.
2
Log odds of positive lymph nodes may predict survival benefit in patients with node-positive non-small cell lung cancer.淋巴结阳性的非小细胞肺癌患者中,阳性淋巴结的对数比值可能预测生存获益。
Lung Cancer. 2018 Aug;122:60-66. doi: 10.1016/j.lungcan.2018.05.016. Epub 2018 May 23.
3
Prognostic value of lymph node ratio in stage III non-small-cell lung cancer: A retrospective cohort study.淋巴结比率在 III 期非小细胞肺癌中的预后价值:一项回顾性队列研究。
Medicine (Baltimore). 2023 Oct 6;102(40):e35341. doi: 10.1097/MD.0000000000035341.
4
[Value of metastatic lymph node ratio in predicting the prognosis of non-small cell lung cancer patients].[转移淋巴结比率在预测非小细胞肺癌患者预后中的价值]
Zhonghua Yi Xue Za Zhi. 2011 Jun 28;91(24):1682-6.
5
Validation of the lymph node ratio as a prognostic factor in patients with N1 nonsmall cell lung cancer.淋巴结比率作为 N1 期非小细胞肺癌患者预后因素的验证。
Cancer. 2011 Oct 15;117(20):4724-31. doi: 10.1002/cncr.26093. Epub 2011 Mar 30.
6
Lymph Node Ratio Enhances Predictive Value for Treatment Outcomes in Patients with Non-Small Cell Lung Cancer Undergoing Surgery: A Retrospective Cohort Study.淋巴结比率提高接受手术的非小细胞肺癌患者治疗结果的预测价值:一项回顾性队列研究
J Cancer. 2024 Jan 1;15(2):466-472. doi: 10.7150/jca.90525. eCollection 2024.
7
Value of the metastatic lymph node ratio for predicting the prognosis of non-small-cell lung cancer patients.转移性淋巴结比率对于预测非小细胞肺癌患者预后的价值。
World J Surg. 2012 Feb;36(2):455-62. doi: 10.1007/s00268-011-1360-8.
8
The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer.基于比例的淋巴结分期在可切除非小细胞肺癌中的预后价值。
J Thorac Oncol. 2013 Apr;8(4):429-35. doi: 10.1097/JTO.0b013e3182829c16.
9
Association of log odds of positive lymph nodes with survival in patients with small cell lung cancer: Results from the SEER database.小细胞肺癌患者阳性淋巴结的对数优势比与生存的相关性:来自监测、流行病学和最终结果(SEER)数据库的结果
Clinics (Sao Paulo). 2024 May 1;79:100369. doi: 10.1016/j.clinsp.2024.100369. eCollection 2024.
10
The prognostic value of lymph node ratio in patients with surgically resected stage I-III small-cell lung cancer: a propensity score matching analysis of the SEER database.淋巴结比率在手术切除的 I-III 期小细胞肺癌患者中的预后价值:SEER 数据库的倾向评分匹配分析。
Eur J Cardiothorac Surg. 2021 Nov 2;60(5):1212-1220. doi: 10.1093/ejcts/ezab287.

引用本文的文献

1
Neoadjuvant, Perioperative, and Adjuvant Immunotherapy in Early-Stage Surgically Resectable Non-Small Cell Lung Cancer: Updates and Future Perspectives.早期可手术切除非小细胞肺癌的新辅助、围手术期及辅助免疫治疗:更新与未来展望
Cancers (Basel). 2025 Jun 21;17(13):2077. doi: 10.3390/cancers17132077.
2
Comparative analysis of methodologies for predicting overall survival in patients with non-small cell lung cancer based on the number and rate of resected positive lymph nodes: A study based on the SEER database for 2010 through 2019.基于阳性淋巴结切除数目和阳性淋巴结切除率预测非小细胞肺癌患者总生存期的方法学比较分析:基于 SEER 数据库 2010 年至 2019 年的研究。
Clin Respir J. 2023 Nov;17(11):1145-1157. doi: 10.1111/crj.13699. Epub 2023 Sep 18.
3

本文引用的文献

1
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
2
Lymph-node ratio predicts survival among the different stages of non-small-cell lung cancer: a multicentre analysis†.淋巴结比率可预测非小细胞肺癌不同分期的生存情况:一项多中心分析†。
Eur J Cardiothorac Surg. 2019 Mar 1;55(3):405-412. doi: 10.1093/ejcts/ezy311.
3
Survival Patterns for Patients with Resected N2 Non-Small Cell Lung Cancer and Postoperative Radiotherapy: A Prognostic Scoring Model and Heat Map Approach.
YAP/TAZ: Molecular pathway and disease therapy.YAP/TAZ:分子途径与疾病治疗
MedComm (2020). 2023 Aug 9;4(4):e340. doi: 10.1002/mco2.340. eCollection 2023 Aug.
4
Surgical Treatment Outcomes of Patients with Non-Small Cell Lung Cancer and Lymph Node Metastases.非小细胞肺癌伴淋巴结转移患者的外科治疗结果
Cancers (Basel). 2023 Jun 7;15(12):3098. doi: 10.3390/cancers15123098.
5
Lymph node ratio predicts overall survival in patients with stage II non-small cell lung cancer: a population-based SEER analysis.淋巴结比率可预测Ⅱ期非小细胞肺癌患者的总生存期:一项基于人群的监测、流行病学和最终结果(SEER)分析
Discov Oncol. 2022 Aug 18;13(1):75. doi: 10.1007/s12672-022-00542-w.
6
Postoperative radiotherapy in resected non-small cell lung cancer: The never-ending story.切除的非小细胞肺癌术后放疗:永无休止的故事。
World J Clin Oncol. 2021 Oct 24;12(10):833-844. doi: 10.5306/wjco.v12.i10.833.
N2 期非小细胞肺癌术后放疗患者的生存模式:预后评分模型和热图方法。
J Thorac Oncol. 2018 Dec;13(12):1968-1974. doi: 10.1016/j.jtho.2018.08.2021. Epub 2018 Sep 5.
4
Prognostic value of lymph node ratio after induction therapy in stage IIIA/N2 non-small cell lung cancer: a monocentric clinical study.诱导治疗后淋巴结比率在IIIA/N2期非小细胞肺癌中的预后价值:一项单中心临床研究
J Thorac Dis. 2018 Jun;10(6):3225-3231. doi: 10.21037/jtd.2018.05.138.
5
Improved Lymph Node Staging in Early-Stage Lung Cancer in the National Cancer Database.国家癌症数据库中早期肺癌淋巴结分期的改善
Ann Thorac Surg. 2017 Dec;104(6):1805-1814. doi: 10.1016/j.athoracsur.2017.06.066. Epub 2017 Nov 6.
6
Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non-Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry.检查的淋巴结数量对切除的非小细胞肺癌精确分期及长期生存的影响:一项基于美国监测、流行病学和最终结果(SEER)数据库及中国多机构登记处的人群研究
J Clin Oncol. 2017 Apr 10;35(11):1162-1170. doi: 10.1200/JCO.2016.67.5140. Epub 2016 Dec 28.
7
Lymph node ratio as a prognostic factor in patients with pathological N2 non-small cell lung cancer.淋巴结比率作为病理N2期非小细胞肺癌患者的预后因素
World J Surg Oncol. 2016 Nov 25;14(1):295. doi: 10.1186/s12957-016-1048-5.
8
Lymph node ratio is a prognostic factor for non-small cell lung cancer.淋巴结比率是非小细胞肺癌的一个预后因素。
Oncotarget. 2015 Oct 20;6(32):33912-8. doi: 10.18632/oncotarget.5669.
9
[Determination of sentinel lymph node by Tc(99m) in small-cell lung cancer].[利用锝(99m)确定小细胞肺癌前哨淋巴结]
Tuberk Toraks. 2014;62(1):45-50. doi: 10.5578/tt.5987.
10
Demonstration of the skip metastasis pathway for N2 non-small cell lung cancer.N2期非小细胞肺癌跳跃转移途径的论证。
J Thorac Cardiovasc Surg. 2014 Apr;147(4):e50-2. doi: 10.1016/j.jtcvs.2013.12.058. Epub 2014 Jan 15.